These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10731289)

  • 1. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first".
    Kereiakes DJ; Fry E; Matthai W; Niederman A; Barr L; Brodie B; Zidar J; Casale P; Christy G; Moliterno D; Lengerich R; Broderick T; Shimshak T; Cohen M
    J Invasive Cardiol; 2000 Feb; 12 Suppl A():1A-5A. PubMed ID: 10731289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators.
    Young JJ; Kereiakes DJ; Grines CL
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E14-8;discussion E25-8. PubMed ID: 11156724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.
    Kereiakes DJ; Grines C; Fry E; Esente P; Hoppensteadt D; Midei M; Barr L; Matthai W; Todd M; Broderick T; Rubinstein R; Fareed J; Santoian E; Neiderman A; Brodie B; Zidar J; Ferguson JJ; Cohen M;
    J Invasive Cardiol; 2001 Apr; 13(4):272-8. PubMed ID: 11287711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.
    Welsh RC; Gordon P; Westerhout CM; Buller CE; O'Neill B; Armstrong PW
    Catheter Cardiovasc Interv; 2007 Sep; 70(3):341-8. PubMed ID: 17295333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI.
    Carnendran L; Borkowski R; Markabawi B; Warner MF
    J Invasive Cardiol; 2003 May; 15(5):235-8. PubMed ID: 12730628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
    Ferguson JJ
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E10-3;discussion E25-8. PubMed ID: 11156723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
    Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Legutko J; Mielecki W; Depukat R; Janzon M; Stefaniak J; Zmudka K; Dubiel JS; Partyka L; Dudek D
    Am Heart J; 2009 Oct; 158(4):569-75. PubMed ID: 19781416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abciximab: a review and update for clinicians.
    Mazzaferri EL; Young JJ
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):609-18. PubMed ID: 18510478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
    J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
    Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shimada YJ; Nakra NC; Fox JT; Kanei Y
    Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
    Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schömig A
    Eur Heart J; 2008 Feb; 29(4):455-61. PubMed ID: 18158289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.